Aspen Neuroscience is a private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease.
Aspen is developing enabling technologies for patient-specific induced pluripotent stem cell-based therapies.
Aspen Neuroscience was founded in 2018 by Jeanne Loring. The company is headquartered in La Jolla, California.
Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson disease.
Aspen’s first product is currently undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic forms of Parkinson disease, the company said. Its second product uses gene correction and neuron therapy to try to treat genetic forms of Parkinson disease.
Aspen Neuroscience is backed by OrbiMed, ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates and others. The company raised $70M in a Series A round on Apr 01, 2020. This brings Aspen Neuroscience's total funding to $76.5M in funding to date.